絞り込み

16525

広告

Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.

著者 Aguiar PN , Haaland B , Park W , San Tan P , Del Giglio A , de Lima Lopes G
JAMA Oncol.2018 May 31 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (19view , 0users)

Full Text Sources

Miscellaneous

The survival of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations has improved substantially in the last decade with the development of targeted tyrosine kinase inhibitors (TKIs). Osimertinib, a third-generation TKI that is approved by the US Food and Drug Administration for the treatment of patients who develop EGFR T790M mutations, has recently shown improved clinical outcomes compared with gefitinib and erlotinib for treatment-naive patients.
PMID: 29852038 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード